Share this article
Share this article
ResearchAndMarkets.com s offering.
A revised analysis puts the global market size at US$5.4 billion for the year 2027.
The COVID-19 induced recession has now cast serious questions on the ability of governments and companies to earmark financial commitments in times of crisis.
The only hope for the market in successfully mitigating the short- and long-term damage of the crisis, is securing fiscal stimulus from governments. However, the commitment of pandemic scarred deficit widened governments in funding innovation ecosystems is yet to be seen.
Most R&D budgets which are so vital for innovation are largely dependent upon financial support from governments. Healthy financial performance of companies also determines the extent of willingness to reinvest earnings into R&D and new product development.
As mentioned in
the stock exchange announcement on 27 October 2020, Restorsea has entered into an agreement to license Aquabeautine XL to the company Conversion Labs, which was listed on NASDAQ on 10 December 2020. Conversion Lab has today officially launched its new Veritas MD telecommunications health platform, which will roll out the new skincare brand Nava MD nationwide. Nava MD is based on Aquabeautine XL.
The positive trend from Restorsea s commercialization of ABT s proprietary technology increases the likelihood that ABT will receive additional renewal payment and increased revenue from the sale of ingredients and royalties from Restorsea and its licensees.
For further information, please contact Espen Kvale, CEO, telephone +47 916 28 092